Bharat Biotech

 - Sakshi Post
May 21, 2021
Bharat Biotech announced that it is planning to increase the manufacturing capacity of Covaxin, its Covid-19 vaccine, by an additional 200 million doses per year.
 - Sakshi Post
May 16, 2021
Bharat Biotech on Sunday shared that Covaxin has found to be effective against the coronavirus strains found in India and the UK.
Can Chandrababu Ask His Bharat Biotech Friend to Send Vaccines to AP? - Sakshi Post
May 10, 2021
KAKINADA: Reiterating that the State government is working with an aim to save every single life by fully equipping all the hospitals and Covid Care Centres across the State, Minister for Agriculture...
 - Sakshi Post
Apr 30, 2021
The Telangana government is in talks with Bharat Biotech and Dr Reddy’s Laboratories (DRL) for procuring Covid-19 vaccines in the state to ensure all those above 18 get the jab.
 - Sakshi Post
Apr 28, 2021
Hyderabad-based Bharat Biotech is all ready to increase the production of its indigenously developed Covaxin to 12 million doses a month by July. Currently, the company is producing only 5 million.
Covaxin demonstrates 78 percent efficacy in Phase-3 interim analysis -Bharat Biotech - Sakshi Post
Apr 21, 2021
HYDERABAD: Bharat Biotech-developed Covaxin demonstrated 78 percent efficacy  in treating COVID-19  as per reports released by the company.
 - Sakshi Post
Mar 04, 2021
New Delhi: Bharat Biotech on Wednesday said its COVID-19 vaccine, Covaxin, has proved an interim vaccine efficacy of 81 percent in Phase 3 clinical trials.
 - Sakshi Post
Mar 02, 2021
The Indian Pharmaceutical companies became the recent target of cyber security breach and hacking. The hackers or the hacking organizations that are based off in China have been posing a threat to...
 - Sakshi Post
Jan 19, 2021
Bharat Biotech on Monday warned that those who have weaker immunity and people with allergies must not take the Covaxin shot.
 - Sakshi Post
Jan 17, 2021
India has started their COVID-19 vaccination drive and it is said to be one of the world’s largest drives ever. The vaccine will be administered in two separate doses with around 28-days gap in...
 - Sakshi Post
Jan 05, 2021
HYDERABAD: Bharat Biotech has faced a lot of backlash after the recent EUA decision.
 - Sakshi Post
Jan 03, 2021
The Drugs Controller General of India (DCGI) provided Emergency Use Authorization (EUA) to two vaccines in India. The announcement was made earlier today.
 - Sakshi Post
Dec 28, 2020
HYDERABAD: With the spread of coronavirus, every company, manufacturers is trying to develop vaccines as soon as possible. There are as many as five vaccine companies in Hyderabad working on bringing...
 - Sakshi Post
Dec 23, 2020
Bharat Biotech has been conducting research and for the COVID vaccine. For the stage three of COVAXIN trials, around 13,000 volunteers were recruited. The trial will be conducted across multiple...
 - Sakshi Post
Dec 06, 2020
Bharat Biotech has developed Covaxin which is a two-dose vaccine against coronavirus. The Hyderabad based vaccine developer and manufacturer Bharat Biotech has been working on this and have now...
 - Sakshi Post
Aug 12, 2020
HYDERABAD: The clinical trials of India's first Coronavirus vaccine COVAXIN being conducted at Nizam's Institute of Medical Sciences (NIMS) have reached the final phase
Representational Image - Sakshi Post
Jul 25, 2020
NEW DELHI: Covaxin, India's first COVID-19 vaccine candidate, launched a clinical trial at All India Institutes of Medical Sciences (AIIMS), Delhi on July 24th.
 - Sakshi Post
Jul 20, 2020
HYDERABAD: As part of India's first Coronavirus vaccine COVAXIN clinical trials, the research team currently based at NIMS in Hyderabad for this purpose, has administer
Bharat Biotech - Sakshi Post
Apr 03, 2020
CoroFlu could be in human clinical trials by the fall of 2020.
ICMR to monitor Hyderabad firm's work on anti-Zika vaccine - Sakshi Post
Mar 03, 2016
ICMR to monitor Hyderabad firm's work on anti-Zika vaccine
Indian firm developing vaccine for Zika virus - Sakshi Post
Feb 03, 2016
Indian firm developing vaccine for Zika virus
Back to Top